Neuroendocrine tumors (NETs) are relatively rare neoplasms that often present as
diagnostic dilemmas due to obscure or non-specific symptoms. The ability of carcinoid …

Patients with neuroendocrine tumors may pursue a number of treatment options, but there is
little consensus on a single, standard treatment approach. Somatostatin analogs are …

Background: Above-label doses of somatostatin analogs (SSAs) are increasingly utilized in
the management of inoperable/metastatic gastroenteropancreatic neuroendocrine tumors …

Neuroendocrine tumors (NETs) represent a group of biologically and clinically
heterogeneous neoplasms arising from the diffuse neuroendocrine system. Although NETs …

Abstract Background Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated
annual incidence of~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse …

Our understanding about the epidemiological aspects, pathogenesis, molecular diagnosis,
and targeted therapies of neuroendocrine neoplasms (NENs) have drastically advanced in …

Traditional therapies have offered patients with advanced gastrointestinal neuroendocrine
tumors limited benefit. Selected patients with hepatic metastases may benefit from surgical …

Neuroendocrine tumors of the gastro-entero-pancreatic system (GEP-NETs) are a
heterogeneous group of neoplasms, with different malignant potential and behavior. Many …

Gastro-enteric-pancreatic neuroendocrine tumors (GEP-NETs), although a rare group of
tumors, have shown a rising burden over the decades, with the age-adjusted incidence rate …

Background Treatment options for metastatic gastroenteropancreatic neuroendocrine
tumors (NETs) have evolved in recent years. The somatostatin analogs octreotide and …